CEOInterviews.AI
Start App
Get an email when Mark Cuban gives a new interview
One email per new interview. Unsubscribe in one click.
Mark Cuban
Co-founder; minority owner, Dallas Mavericks, Cost Plus Drugs

Making Health Care Costs Simple and Transparent w/ Mark Cuban

📅 Jan 09, 2026 Health Care Rounds Podcast 43 MIN 40621 VIEWS 73 SEGMENTS · 2 SPEAKERS
We’re kicking off 2026 with Mark Cuban! Prescription pricing remains one of the most opaque and frustrating parts of the health care system, leaving employers, providers, and patients struggling to understand where costs come from and who truly benefits. Mark Cuban joins Health Care Rounds to talk about why prescription pricing became so complex, how a lack of transparency drives higher costs, and how his company Cost Plus Drugs is stripping away unnecessary layers and markups to deliver simpler, more predictable pricing built on trust. ================================================...

Questions asked in this interview

12
  1. 1:00And that is, you know, as you look back to the start of Cost Plus, what surprised you about the early response that you got?
  2. 2:50The way it actually happens now is very complicated, right?
  3. 4:54Who in the supply chain is going to be no longer economically viable?
  4. 12:44Well, a lot of that is the government, right?
  5. 14:25... think of any other industry with a pricing structure like this where people don't know when they're going to get paid, when they, as you say, where they can't implement accrual accounting because they can't match up time periods, right?
  6. 20:19It's almost like a philosophy, but you're really using it as a signal, like a market signal, right?
  7. 22:41So, do you see biosimilars as sort of being your entree into the branded world, and it really expanding in that world of biosimilars?
  8. 26:08Do they understand what you just explained?
  9. 28:12Now, let's set the politics aside, right, for a second, but what market triggers might push us into that territory?
  10. 31:43Do some of the wholesalers go away?
  11. 32:53But once you really start dipping in, and let's say you're getting at, you know, 5%, 10% of share of some of this branded stuff, what kind of reaction do you expect to see in the marketplace?
  12. 40:21Well, I would be surprised if one of these upstart pharma companies launching their first drug, right?
John Marchica 0:19 ↗
Welcome to Healthcare Rounds. I'm John Marchica, CEO of Darwin Research Group. Today, I'm joined by Mark Cuban, entrepreneur, investor, and co-founder of the Mark Cuban Cost Plus Drug Company. Today, we're going to talk about what's really happening underneath the surface of drug pricing, so transparency, market incentives, and PBM reform. And Mark, I know that you've probably answered a lot of the same questions again and again about Cost Plus. So, we're going to try to dig in a little deeper into these issues of transparency, and also some of the new things that Cost Plus is involved in. So, thanks for taking the time. Really do appreciate it.
Mark Cuban 0:58 ↗
I'm excited to be here.
John Marchica 1:00 ↗
Cool. Well, we'll start with an easy warm-up. And that is, you know, as you look back to the start of Cost Plus, what surprised you about the early response that you got? And not just from patients or consumers, but maybe from industry or from critics.
Mark Cuban 1:19 ↗
I mean, everybody just dismissed us. You know, I was just some rich famous guy that was going to come in and talk about changing healthcare, you know, and then just be just one more rich famous guy to fall out and accomplish nothing. And, you know, I've been involved in industry disruption before, and what I saw very quickly was that this was going to be the easiest industry I've ever been involved in to disrupt. It literally, because it's such a simple business. You know, the economics of healthcare are, put aside the care part. That's hard, right? But the economic side effectively is simple. What does it cost? How do you pay for it? And who takes the risk for unpaid costs? That's it. Right? And what nobody knew was what is the cost?
Just the most simple, simple, simple element, what does it cost? And so, when we started Cost Plus, it was January of 2022. We had 111 drugs. But, the smartest thing that we did was publish our price list. So that anybody could get it. You go to business.costplusdrugs.com, you can request it. We have an API, not as in a drug API, but as in a programming interface, where we can feed you data every night. You know, just by being transparent, we turned upside down the information asymmetry that had been in place when it came to drug pricing.
John Marchica 2:50 ↗
You know, in my company, so many times we've tried to do diagrams of, you know, all the rebates and how drugs are priced. And, you know, the way that you laid it out is very simple. The way it actually happens now is very complicated, right?
Mark Cuban 3:04 ↗
Yeah, but that's a feature, not a bug, to the companies that are introducing that complication. Right? They don't want you to know. They don't, you know, they want you to be afraid. They want you to think they're the ones that can solve the problems. They aren't. They are the problem.
John Marchica 3:21 ↗
So, if you were mapping out Cost Plus across this sort of traditional pharmacy supply chain, like in a diagram, where do you think that the greatest friction or resistance actually sits?
Mark Cuban 3:35 ↗
Oh, that's easy, right? Our mission is to carry every single drug we're legally allowed to carry. We don't have nearly as many brands as we'd like to, simply because the PBMs, the big three people or the biggest PBMs realized that if we were able to negotiate or we were able to work out deals with the big brand pharmacy manufacturers, and we published our actual cost like we do now, and only mark it up 15%, just like we imploded their specialty generics business, we would implode their entire pharmacy business. Because deep rebates are only available on branded medications. And especially, but we'll stick with brands. And they're a mystery to everybody. And they game them. They have rebate GPOs, all these other games they play. And if we just broke through that and brought transparency to it, and marked something up 15% instead of 100% or more, they'd be in deep trouble. And so, they have told the brand manufacturers that we'd like to work with, if they work with us, then they will see a reduction in the placements on their formularies across their entire portfolios.
John Marchica 4:54 ↗
So, by 2030, who's in trouble? Who in the supply chain is going to be no longer economically viable?
Mark Cuban 5:02 ↗
Insurance companies. And the PBMs that they own, and all the, you know, the largest insurance company has 2,600 subsidiaries that do 161 billion dollars in intercompany transfers. That's 0.53% of American GDP. Just in intercompany transfers. They have so much regulatory and scale capture of the healthcare industry that it needs to change. Look, I'm a free market guy, but we don't have a free or efficient market in healthcare right now, simply because these companies are so big. They need to be broken up just like we broke up AT&T in 1984, these guys need to be broken up vertically so that, you know, their carrier business can be stand-alone, their provider business can be stand-alone, their PBM business can be stand-alone, you know, other parts of their business can be stand-alone, and let them compete, right? And, you know, the return would probably increase to their shareholders, because, you know, if you roll out, you know, the big PBM from a carrier, the stock of that PBM, since that's where a lot of their profits are, is probably going to do better than the carriers' ups and downs. But, that's not for me to decide. I just think that they have so much control over the economics of the industry that it needs to change.
John Marchica 6:33 ↗
I often wonder, how do we get here? I mean, AT&T is actually a really good example of what you're talking about. I mean, all the component parts eventually became the industry that we see today, versus the behemoth back in the '70s. But, I wonder how we got here. Maybe not for us to answer today, but I mean, every one of the big insurance companies, they all have a PBM, right?
Mark Cuban 6:59 ↗
Yeah. No one stopped them. Right? Nobody stopped them, right? Why wouldn't they do what they did? They have every incentive to do it. I mean, you know, they can get big enough so that people can't say no to you.
John Marchica 7:13 ↗
Yeah, it's sort of too big to fail.
Mark Cuban 7:15 ↗
Yeah, and look, it's not just one company, it's multiple companies, but they know how to divvy up the industry. And I'm not saying they collude, but there are things they won't do, and they all adhere to the same won't-do's. Right? You know, the way they price, the PBMs aren't going to price at net, even though ESI says they're going to, they're going to add an additional per employee per month charge to compensate for the lost margin. Right? It's just there are certain things they won't do that distorts the economics, and makes it so that their interests are not aligned with patients. Or, you know, or doctors for that matter. I mean, you talk to independent physicians, those that own their clinics, they're just struggling to hang on, and a big part of that is... So, okay, so if you follow me on LinkedIn at Mark Cuban or M. Cuban, I've been engaging with doctors, particularly those that are independent or work in practices or have clinics, and they've fully... and I'm just thinking about this in real time now, because I just read a bunch of this this morning. They are very analogous in how they're paid to independent pharmacies. So, hear me out, because I'm thinking of this in real time. Right? So, when you take a prescription for Eliquis, to use them as an example, it's a brand medication, to a local independent pharmacy. The retail price of that Eliquis is about $600. The independent pharmacy probably paid $570. The only way for them to get their money back is by the insurance carrier reimbursing them at least $570. That's what they have in their cost of goods. They don't. They under-reimburse them. And so, they lose money. They lose a whole lot of money on GLP-1s. And so, what ends up happening is, since that's such a big part of the business, and they're losing money on every script, either they decline to fill those, and they send them to CVS typically, or they take the loss hoping to, you know, sell enough toilet paper and Cokes to balance it out, and they don't. It's never going to happen. So, many of them are going out of business. Analogous to that is what's happening in the reimbursements from carriers to those independent clinics and physicians and practices. They'll delay, delay, delay. Like I got into this big discussion about why don't they use accrual accounting as opposed to cash accounting. And there were some IRS issues, but effectively it was, we don't know how much or when we're getting paid by the insurance carriers. Now, think about that. You have a contract with them. You have a set price or, you know, a calculable price for whatever service you're offering. The member of that insurance company comes in and says, 'Hey, you know, I need, you know, my arm set or whatever it is, right?' And you expect to get it, but in reality they don't know if they're going to get paid the full amount. They don't know when they're going to get paid. They're talking about how it trickles in, 12% here, 30% there. That should be illegal. But they are, and so then you also see in parallel to that certain of these carriers buying up providers. Right, so that they own them. United, of course, is the biggest one. Right. Yep. I won't mention any names, but you know, but that's what they do. And now you also see where hospital systems, you know, have associated insurance plans that try to stay vertically integrated, but where they use external, do the same things. You know, and so there, and the point I'm making in all this, the carriers, it appears to me, and I don't, I'm not going to give specifics because I'm still learning all this, but it's specifics in terms of the carriers appear to me are trying to do the same thing to physicians and clinics and practices that they're doing to independent pharmacies, which is, you know, underpay them to death. That is the underpinning of what's so up about this industry. That if the people who are closest to the patient, 3 ft away, 5 ft away at the counter from the pharmacist to the patient, the doctor with a stethoscope on the chest, right? Can't get paid. And just to try to get paid on both sides, the paperwork is insane. The committees that you have to deal with to get approved by the 97-year-old veterinarian that, you know, never practiced medicine in his life, but is in charge of the denial committee that you have to talk to to overturn the denial, right? It just wastes time. The paperwork wastes time, wastes money, and makes it so patients get in... I don't want to say inferior care because doctors do a great job, but it makes it much more difficult for doctors, and you see and hear it every day. That's what you do, right? And so, it starts somewhere, and it starts with who defines the cash flows. Whoever defines the cash flows defines the industry.
John Marchica 12:44 ↗
Well, a lot of that is the government, right? Medicare and huge payer on that side.
Mark Cuban 12:52 ↗
But they pay on time though, right? Medicare. Okay, Medicare Advantage and Medicare, two different things, very distinct, right? Medicare pays on time. There's no pre-authorization denials. Now, you might not like what the prices are paid, and there's a difference whether it's outpatient and inpatient, and the outpatient doctors get paid less, and we can argue whether or not that's fair. But what's more important, it's not really the government. Again, to me, whatever the government touches is almost always less effective and less productive, except in this case. Because what makes it so that Medicare rates are unaffordable is all the mishigas and all the paperwork and all the things that I just mentioned that create overhead cost and cash flow out for those same doctors who feel like they're getting underpaid by Medicare. And Medicaid, basically the same thing. Here's the price. You don't have to take Medicaid, right? Not all doctors take Medicaid, but if you're a practice that specializes in Medicaid, you can make real money. You can do well and control your own destiny in a big respect because not everybody takes it. And then I'm not an expert in Medicaid, and again, we can argue on what the prices are, but my feeling is if doctors were independent and didn't have to spend most of their day with paperwork and hiring all these different people to deal with that, Medicare would be very profitable. You just can't get there in the current system.
John Marchica 14:25 ↗
You know, I'm dying to ask you this one question that I've asked on the show of other people before, but you're probably more qualified than anybody else. Can you think of any other industry with a pricing structure like this where people don't know when they're going to get paid, when they, as you say, where they can't implement accrual accounting because they can't match up time periods, right? They got to do everything cash.
Mark Cuban 14:48 ↗
Only, and it's even worse than that, right? So, I testified before the Senate Committee on Aging. And one of the points that I brought up is if you are a patient buying that Eliquis and you are in the deductible phase... Well, let me take a step back. When there is a brand medication like Eliquis, the cash flow process is the manufacturer of that medication sells the product to a wholesaler, and there's three big ones that dominate the industry, but they sell it at the retail price. That's where it all starts to fall down because if you're running a hardware store and the distributor that you buy your hammers from only buys at the full retail price, the $49 or whatever for that hammer, right? Now, you're the hammer store and you buy at 5% less than that price, which is what pharmacies buy. So, let's say $50. So, you're buying for $47.55, right? There's no money, no margin to be made whatsoever. That's the way brand drugs are bought and sold in this country right now, and it trickles down to patients in that when they're in their deductible phase, because everybody else has paid really close to retail price, they get charged retail price as well during the deductible phase. So, you're paying the $600 for your Eliquis until you meet your deductible. Insane. Excuse my French, should be illegal. But it's put in place by the carriers that own the PBMs that collude and have joint ventures with those wholesalers. Any other industry, to your point, they're buying that Eliquis at 50% off. Or whatever the net price, whatever it is after fees and rebates, right? And then they're selling it to the pharmacy at a markup that makes them the same amount of money as they were before, because when a wholesaler, to explain it more, when a wholesaler buys that Eliquis from Bristol Myers and if it's $600 retail price, they get a 2.5% prompt payment rebate. So, with $600, so they're getting $15 back, 2.5%. And then they get another 1.5% for DSA, which is digital services agreement effectively, right? So, they're making 4 to 5%. That's it. So, 4 to 5% of $600 is $30. If they would just buy it at $300 and mark it up $30 when they sell to the pharmacy, so the pharmacy was buying it at $330 and they could sell it to the patient for $350 or $375, whatever it is, and compete there. And so when the patient walked in during their deductible phase, it would be $375 instead of $600. Patients would be able to afford their medication better, and it's all because these people don't give a...
John Marchica 18:00 ↗
Yeah. Yeah. What do you think? Well, I'm going to make a pharma argument since I've seen this industry for 30 plus years. My sense is that if we go back to, you know, the '90s or whatever, that pharma has been behaving like a scared cat. In other words, they go into these negotiations. Now, they blame the PBMs, right? You've seen this. But they go into these negotiations, again going all the way back to early days of managed care, and they say, 'Well, we're not going to be able to get our drug on formulary unless we give a rebate.' Right? We have to. It's almost like pay to play, like shelf space.
Mark Cuban 18:42 ↗
For sure. Yeah, that's exactly what it is. It's shelf space, auctioning off access to the formulary, right? And the answer to that is required, again, it takes legislation, require that formularies be segregated from PBMs. It's a different process. Should be. And it's changing enough now that Lilly's going direct, Novo's going direct, Bristol Myers Squibb is putting together a great program that they'll launch for direct, you know, and so they don't want to deal with the PBMs. Lilly and Regeneron actually changed for their own employee benefits. They moved away from big three PBMs. Because 7-Eleven, Tyson Foods, you know, a growing number of companies are doing that. But to your point, the pharma manufacturers are terrified. As I said earlier, the reason why Cost Plus doesn't carry brands is they're afraid of losing their positioning on the formulary. Make it so they're required to be disaggregated. Because for a big company to hire a consulting firm to look at and review their formulary annually costs less than $25,000.
John Marchica 19:56 ↗
Yeah.
Mark Cuban 19:57 ↗
It's nothing.
No, and that's what I tell... I just got off the phone, that's why I was a little bit late, talked to a huge company, and I told them, you know, you're getting ripped off. You know, and went through the whole long list of reasons, including, why do you use them for your formulary? They're just auctioning it off.
John Marchica 20:19 ↗
Yeah. Yeah. Well, you know, just sticking with this, and I want to get to the health systems here in a second, but just thinking about a lot has been talked about transparency, transparency. It's almost like a philosophy, but you're really using it as a signal, like a market signal, right?
Mark Cuban 20:37 ↗
Yeah. To say, you know, here's what you're going to pay, and up front, this is the cut that we're taking.
John Marchica 20:42 ↗
Here's our cost.
Mark Cuban 20:44 ↗
Right. And here's our markup, because what's missing more than anything on the economic side of the health care industry, trust. And how do you engender trust? You're completely transparent.
John Marchica 20:57 ↗
So, now that you've been at this for a few years, what's the most interesting behavior change that you've seen from either pharma or from employers, just simply the fact that you're publishing these prices?
Mark Cuban 21:12 ↗
Yeah, from employers. Like when I was testifying at Senate, so was Dr. Moulds, who runs CalPERS for California. For their people, for their benefits plan. And he said he used our price list to negotiate with the big three PBM. They ended up going with... I was like, well, I'm upset you used a big three PBM instead of using somebody who's more transparent, but he was like, no, you really got them to lower their prices and saved all of our members a lot of money, because we were able to use you as a reference price. And it's one thing on tablets and pills, right? But it's a whole other thing on biosimilars. So, like we just released our biosimilar for Stelara. And Stelara was like $125,000 a year for the brand version. We're $410 times 3, so $1,230 a year. The big PBMs, they're not... Now, with their biosimilars, they've cut the cost from $125,000, but it may be $9,000 or $10,000 or $15,000 with some rebates versus $1,230. You know, that's the biggest change, because people are using our price list and realizing where the inefficiencies or where the rip-offs are from their PBMs, and saying, you got to match Cost Plus. And oh, by the way, just because it's a biosimilar, doesn't mean we're going to let you take advantage of us.
John Marchica 22:41 ↗
So, do you see biosimilars as sort of being your entree into the branded world, and it really expanding in that world of biosimilars?
Mark Cuban 22:51 ↗
Yeah, there's a couple different areas. One, we'll work with third parties to get biosimilars wherever we can. But we also do manufacturing for our sterile injectables in Dallas. And right now we do generic sterile injectables, everything from Pitocin to pediatric cancer drugs for hospitals, and because they're in short supply, historically those manufacturers have just jacked up the price. And so, because we do our own manufacturing, it's all robotics driven in Dallas, our prices are dramatically lower. And we also have a wholesaler that we built, a virtual wholesaler, where we just do a cost plus markup as well for injectables and J-code drugs, biosimilars, and a growing number of other types of specialty drugs, where we're able to save, like Penn Medicine estimated we'll save them 4 to 5 million. CHS, 1.8 million. I mean, honestly, and our business just keeps on growing by the week, and our hardest part of that business is getting the purchasing agents in those hospitals to change their behavior. Even after they're told, right? But the bigger picture is in terms of employers. What has changed over the past four years is that at the beginning, it was easy for the big PBMs to dismiss us. They're small, they have no track record. And then, you know, a year, two years later, it was like, okay, well, here's Cost Plus Drugs price list. You got to at least come close, and they would just, the big PBMs would just increase the rebate. Okay, you know, you got us, we'll increase the rebate. But now, sitting and talking to CEOs, they're starting to understand that your sickest employees pay those rebates. That there would be no rebates if nobody used a medication, right? And when you have, you know, tens of millions of dollars or smaller, whatever the number is, that you're getting in rebates, your sickest employees and your most chronically ill employees are the ones that use the most expensive drugs with the biggest rebates. And they're the ones that are getting charged that full retail price during the deductible phase. And I sit with employers and the CEOs, and I say, okay, do you know what the ERISA laws are? That you have a fiduciary responsibility to your members, particularly your employee members, and if you are charging them the full retail price for this specialty brand medication, so a big chunk of that specialty brand medication price is coming back to you in a rebate. So, you are taking money directly from the employee. Now, the cash, as I said earlier, goes in a roundabout way, but effectively, the $600 check that the employee wrote, $300 of that, in an example, is going in rebates. The PBM keeps part of the rebate, and the rest goes to you. So, your sickest employees are paying you those rebates. How's that going to look in an ERISA lawsuit?
John Marchica 26:08 ↗
I was just going to say, and I would think if you're talking to health system CEOs, they probably understand a lot of this. But, you know, out there, you're talking to CEOs, CFOs, do they really understand kind of the exposure? Do they understand what you just explained?
Mark Cuban 26:26 ↗
No, they don't. That's why my meeting with them is what's changing behavior. So, I go through my list. I just got off the one, like I said, right before I came on this call. And their eyes just kept on getting bigger and bigger and bigger until the point they went, you know, you know how it goes, you put your head down and you just start laughing because there's nothing else you could do. They're starting to realize now. And I go talk to CEO organizations, and I go talk to benefits organizations. And so, on the employer side, it's one thing. Then, on the hospital side, it's a completely different beast, where the hospital networks are both victim and predator.
John Marchica 27:06 ↗
What do you mean by that? Just their relationship to GPOs, or...
Mark Cuban 27:10 ↗
No, no, not necessarily. No, put aside the pharmacy benefit on the medical side. Now, on the pharmacy side, they benefit more, right? They're predator in that they take advantage of the 340B rebates, right? You know, they create facility... Well, that's the... With J-codes, they make, you know, good money on J-codes. When if it was part of the pharmacy benefit, it'd be significantly less for the member and the payer. So, you know, they're not completely innocent, but I think again, the insurance companies... I'll give the networks, the hospitals the benefit of the doubt and say that the plans that are designed and the way the economics are defined by the carriers puts the hospital networks in a really precarious place, unless they have true market dominance. If the hospital has true market dominance in a market, all bets are off.
John Marchica 28:05 ↗
So, you've used the term or the phrase tobacco-style litigation.

36 more exchanges in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Cuban, M. (2026, January 9). Making Health Care Costs Simple and Transparent w/ Mark Cuban [Interview transcript]. Health Care Rounds Podcast. CEOInterviews.AI. https://ceointerviews.ai/interview/3082385/

MLA

Mark Cuban. "Making Health Care Costs Simple and Transparent w/ Mark Cuban." Health Care Rounds Podcast, 9 Jan. 2026. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3082385/.

BibTeX
@misc{cuban2026_3082385,
  author       = {Mark Cuban},
  title        = {Making Health Care Costs Simple and Transparent w/ Mark Cuban},
  howpublished = {Interview transcript, Health Care Rounds Podcast. CEOInterviews.AI},
  year         = {2026},
  month        = {jan},
  url          = {https://ceointerviews.ai/interview/3082385/},
  note         = {Speaker-attributed transcript with timestamps}
}